International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in pediatric patients with relapsed or refractory hematological malignancies
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Trametinib (Primary) ; Trametinib (Primary)
- Indications Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms HEM-iSMART Subprotocol D
Most Recent Events
- 24 May 2023 Planned End Date changed to 11 Nov 2030.
- 24 May 2023 Status changed from not stated to recruiting.
- 09 Mar 2023 New trial record